119 related articles for article (PubMed ID: 38403951)
41. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
42. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
[TBL] [Abstract][Full Text] [Related]
44. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy.
Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T
Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600
[TBL] [Abstract][Full Text] [Related]
45. Structure-transfection activity relationships in a series of novel cationic lipids with heterocyclic head-groups.
Ivanova EA; Maslov MA; Kabilova TO; Puchkov PA; Alekseeva AS; Boldyrev IA; Vlassov VV; Serebrennikova GA; Morozova NG; Zenkova MA
Org Biomol Chem; 2013 Nov; 11(41):7164-78. PubMed ID: 24057052
[TBL] [Abstract][Full Text] [Related]
46. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Eichhorn ME; Ischenko I; Luedemann S; Strieth S; Papyan A; Werner A; Bohnenkamp H; Guenzi E; Preissler G; Michaelis U; Jauch KW; Bruns CJ; Dellian M
Int J Cancer; 2010 Mar; 126(5):1235-45. PubMed ID: 19697323
[TBL] [Abstract][Full Text] [Related]
47. Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel.
Miao YQ; Chen MS; Zhou X; Guo LM; Zhu JJ; Wang R; Zhang XX; Gan Y
Acta Pharmacol Sin; 2021 Oct; 42(10):1714-1722. PubMed ID: 33469196
[TBL] [Abstract][Full Text] [Related]
48. Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.
Han X; Dong X; Li J; Wang M; Luo L; Li Z; Lu X; He R; Xu R; Gong M
Int J Pharm; 2017 Aug; 528(1-2):33-46. PubMed ID: 28576551
[TBL] [Abstract][Full Text] [Related]
49. Effects of surface charge of low molecular weight heparin-modified cationic liposomes on drug efficacy and toxicity.
Li H; Chen Y; Deng Y; Wang Y; Ke X; Ci T
Drug Dev Ind Pharm; 2017 Jul; 43(7):1163-1172. PubMed ID: 28277844
[TBL] [Abstract][Full Text] [Related]
50. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer.
Doddapaneni R; Patel K; Owaid IH; Singh M
Drug Deliv; 2016 May; 23(4):1232-41. PubMed ID: 26701717
[TBL] [Abstract][Full Text] [Related]
51. Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.
Zhang R; Wang SB; Chen AZ; Chen WG; Liu YG; Wu WG; Kang YQ; Ye SF
J Biomater Appl; 2015 Sep; 30(3):351-60. PubMed ID: 25838353
[TBL] [Abstract][Full Text] [Related]
52. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
53. Integrin α
Fu S; Zhao Y; Sun J; Yang T; Zhi D; Zhang E; Zhong F; Zhen Y; Zhang S; Zhang S
Colloids Surf B Biointerfaces; 2021 May; 201():111623. PubMed ID: 33636597
[TBL] [Abstract][Full Text] [Related]
54. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
55. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
56. pH-sensitive polymer-modified liposome-based immunity-inducing system: Effects of inclusion of cationic lipid and CpG-DNA.
Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
Biomaterials; 2017 Oct; 141():272-283. PubMed ID: 28704679
[TBL] [Abstract][Full Text] [Related]
57. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
58. Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer.
Li M; Li S; Li Y; Li X; Yang G; Li M; Xie Y; Su W; Wu J; Jia L; Li S; Ma W; Li H; Guo N; Yu P
Eur J Med Chem; 2022 Apr; 233():114198. PubMed ID: 35245829
[TBL] [Abstract][Full Text] [Related]
59. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer.
Wang J; Liu D; Guan S; Zhu W; Fan L; Zhang Q; Cai D
Carbohydr Polym; 2020 May; 235():115981. PubMed ID: 32122511
[TBL] [Abstract][Full Text] [Related]
60. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes.
Campbell RB; Balasubramanian SV; Straubinger RM
J Pharm Sci; 2001 Aug; 90(8):1091-105. PubMed ID: 11536214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
